| 1.78 0.2 (12.66%) | 08-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 2.3 |
1-year : | 2.68 |
| Resists | First : | 1.96 |
Second : | 2.3 |
| Pivot price | 1.16 |
|||
| Supports | First : | 1.3 |
Second : | 0.89 |
| MAs | MA(5) : | 1.41 |
MA(20) : | 1.15 |
| MA(100) : | 1.89  |
MA(250) : | 4.22 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 85.7 |
D(3) : | 83.3 |
| RSI | RSI(14): 71.4 |
|||
| 52-week | High : | 9.22 | Low : | 0.89 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ACTU ] has closed Bollinger Bands are 6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.97 - 1.98 | 1.98 - 1.99 |
| Low: | 1.55 - 1.56 | 1.56 - 1.57 |
| Close: | 1.77 - 1.78 | 1.78 - 1.79 |
Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers. Its primary drug candidate is Elraglusib Injection, an innovative glycogen synthase kinase-3 (GSK-3) inhibitor designed to combat metastatic pancreatic ductal adenocarcinoma. Furthermore, Elraglusib is being developed to address other malignancies, including Ewing sarcoma, metastatic melanoma, and colorectal cancer. Originally named Apotheca Therapeutics, Inc., the organization rebranded as Actuate Therapeutics, Inc. in October 2015. Established in 2015, the company maintains its headquarters in Fort Worth, Texas.
Wed, 26 Aug 2026
Actuate Therapeutics Market Sentiment - Benzinga France
Fri, 21 Aug 2026
12 Health Care Stocks Moving In Thursday's Intraday Session - Sahm
Thu, 20 Aug 2026
$Actuate Therapeutics (ACTU.US)$ @Trytosaveabit heheheheh also whats the news no news yet but im up! - Moomoo
Fri, 14 Aug 2026
Actuate Therapeutics (NASDAQ: ACTU) narrows loss but warns on cash runway - Stock Titan
Fri, 14 Aug 2026
Actuate Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Fri, 14 Aug 2026
Actuate Therapeutics (ACTU) CEO RSUs Vest, 120,521 Shares Withheld for Taxes - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 24 (M) |
| Shares Float | 9 (M) |
| Held by Insiders | 15.4 (%) |
| Held by Institutions | 56.3 (%) |
| Shares Short | 450 (K) |
| Shares Short P.Month | 687 (K) |
| EPS | -0.88 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.03 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -213.4 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -20 (M) |
| Levered Free Cash Flow | -12 (M) |
| PE Ratio | -2.05 |
| PEG Ratio | 0 |
| Price to Book value | 44.5 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.16 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|